Mink therapeutics presents clinical activity and long-term persistence of allogeneic inkt cells in solid tumors at sitc 2023

New york, nov. 03, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today presented new agent-797 data in solid tumor cancers at the society for immunotherapy of cancer's (sitc) 38th annual meeting.
INKT Ratings Summary
INKT Quant Ranking